NEW YORK – Aceopodia on Tuesday completed a $47 million Series B funding round to support further development of its lead product, a natural killer (NK)-cell therapy being studied in HER2-positve tumors.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.